A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors

Journal of Supportive Oncology

Volumn 8, Issue 5, 2010, Pages 202-208

  Wong, Siu Fun ^a,b,c   Lindgren, Alexander ^a,b,c   Mummaneni, Madhavi ^a,b,c   Byun, Timothy ^a,b,c   Vasko, Catherine ^a,b,c   Arenos, Rachel ^a,b,c   Alexson, Edward ^a,b,c   Osann, Kathryn ^a,b,c  

^a LOMA LINDA UNIVERSITY   (United States)

^b ST JOSEPH HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; ERLOTINIB; PANITUMUMAB; REGENECARE WOUND GEL; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DESQUAMATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; PAIN; PATIENT SATISFACTION; PILOT STUDY; PROSPECTIVE STUDY; PRURITUS; QUESTIONNAIRE; RASH; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78249247422     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suponc.2010.09.003     Document Type: Article

References (49)

1. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979;48:193-216. [382984]
2. Adjei AA, Rowinsky EK. Novel anticancer agents in clinical development. Cancer Biol Ther 2003;2(suppl 1):S5-S15. [14508076]
3. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232. [7612182]
4. Syed S, Rowinsky E. The new generation of targeted therapies for breast cancer. Oncology (Williston Park) 2003;17:1339-1351; discussion 1352, 1355-1356. [14606361]
5. Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991;9:553-562. [1933488]
6. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in nonsmall-cell lung cancer. Clin Lung Cancer 2004; 6(suppl 1):S20-S23. [15638953]
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345. [15269313]
8. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208. [14993230]
9. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664. [17470858]
10. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-1176. [11422037]
11. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-5246. [16051966]
12. Herbst RS, Prager D, Hermann R, et al; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899. [16043829]
13. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-smallcell lung cancer. J Clin Oncol 2004;22: 3238-3247. [15310767]
14. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22: 77-85. [14701768]
15. Saltz L, Kies M, Abbruzzese JL, Azarnia N, Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2008;22. Abstract 817.
16. Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12:610-621. [17522250]
17. Lacouture ME, Basti S, Patel J, Benson A 3rd. The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors. J Support Oncol 2006;4:236-238. [16724647]
18. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16: 1425-1433. [16012181]
19. Perez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR Inhibitor Rash Management Forum. Oncologist 2005;10:345-356. [15851793]
20. Molinari E, De Quatrebarbes J, André T, Aractingi S. Cetuximab-induced acne. Dermatology 2005;211:330-333. [16286741]
21. Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8(suppl 1):S7-S14. [17239291]
22. Racca P, Fanchini L, Caliendo V, et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic cooperation. Clin Colorectal Cancer 2008;7:48-54. [18279577]
23. Perez-Soler R, Van Cutsem E. Clinical research of EGFR inhibitors and related dermatologic toxicities. Oncology (Williston Park) 2007; 21(11 suppl 5):10-16. [18154213]
24. Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-5396. [18048820]
25. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113:847-853. [18543329]
26. Mitchell EP, Lacouture H, Shearer N, et al. Final STEPP results of prophylactic versus reactive skin toxicity (ST) treatment for panitumumab (pmab)-related ST in patients with metastatic colorectal cancer. J Clin Oncol 2009; 17(suppl):18S. Abstract CRA4027.
27. Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007;21(11 suppl 5): 34-36. [18154217]
28. Lacouture ME, Cotliar J, Mitchell EP. Clinical management of EGFRI dermatologic toxicities: US perspective. Oncology (Williston Park) 2007;21(11 suppl 5):17-21. [18154214]
29. Drug Facts and Comparisons, 60th ed. St. Louis, MO: Wolters Kluwer Health; 2009.
30. Ayer V, Tewodros W, Manoharan A, Skariah S, Luo F, Bessen DE. Tetracycline resistance in group A streptococci: emergence on a global scale and influence on multiple-drug resistance. Antimicrob Agents Chemother 2007;51:1865-1868. [17307980]
31. Clewell DB, Flannagan SE, Jaworski DD. Unconstrained bacterial promiscuity: the Tn916-Tn1545 family of conjugative transposons. Trends Microbiol 1995;3:229-236. [7648031]
32. Rice LB. Tn916 family conjugative transposons and dissemination of antimicrobial resistance determinants. Antimicrob Agents Chemother 1998;42:1871-1877. [9687377]
33. Brenciani A, Bacciaglia A, Vecchi M, Vitali LA, Varaldo PE, Giovanetti E. Genetic elements carrying erm(B) in Streptococcus pyogenes and association with tet(M) tetracycline resistance gene. Antimicrob Agents Chemother 2007;51: 1209-1216. [17261630]
34. Cochetti I, Tili E, Vecchi M, et al. New Tn916-related elements causing erm(B)-mediated erythromycin resistance in tetracycline-susceptible pneumococci. J Antimicrob Chemother 2007;60:127-131. [17483548]
35. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803-812. [16990857]
36. Lee HM, Ciancio SG, Tüter G, Ryan ME, Komaroff E, Golub LM. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontol 2004;75: 453-463. [15088884]
37. Nieman GF, Zerler BR. A role for the antiinflammatory properties of tetracyclines in the prevention of acute lung injury. Curr Med Chem 2001;8:317-325. [11172686]
38. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009;4:107-119. [19452131]
39. Li J, Peccerillo J, Kaley K, Saif MW. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 2009;10:338-340. [19454833]
40. Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008;9:59-60. [18282360]
41. Wilhelm IR, Griessinger N, Koppert W, Sittl R, Likar R. High doses of topically applied lidocaine in a cancer patient. J Pain Symptom Manage 2005;30:203-204. [16183001]
42. Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91: 1343-1350. [11977110]
43. Lacouture ME, Laabs SM, Koehler M, et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2009;114:485-493. [18600445]
44. Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME. Increased risk of highgrade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 2009;115:1286-1299. [19170238]
45. Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 2008;3:5. [18226196]
46. Huang CL, Yang CH, Yeh KH, et al. EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment. Lung Cancer 2009;64:346-351. [18995924]
47. Rudin CM, Liu W, Desai A, et al. Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 2008;26:1119-1127. [18309947]
48. Tan AR, Steinberg SM, Parr AL, Nguyen D, Yang SX. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment. Ann Oncol 2008;19:185-190. [17878175]
49. Fujiwara Y, Kiura K, Toyooka S, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:99-103. [16503086]